## 30 03 2023

FATIMA **SALIH**, CLAIRE **HAWKSWORTH**, ISABELLE **TONGIO**, BETSY WONDERLY **TRAINOR**, DALIA **DAWOUD** 

# REPORT of the Regulatory/HTA/Payer EAP

Session 6



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.



















Version 01 2




















































Version 01 3

## **Sixth EAP session**

## 1.1. Meeting overview

The sixth session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on the 30 March 2023. There were three members of the EAP available in addition to three guest experts.

#### 1.2. Topics and themes discussed

1. VALUE-Dx Progress update:

Progress of VALUE-Dx in the preceding six months including an update on the clinical trials and the key achievements to date.

2. Presentation from guest speaker:

A speaker from bioMérieux provided an overview of challenges in demonstrating the medico-economic value of in-vitro diagnostics (IVDs) compared to drugs, vaccines, and medical devices.

- 3. Short-term trial-based economic analysis:
  - Outcomes considered
  - Time-off-work estimates
  - Presentation of results
- 4. Long-term economic evaluation model:
  - o Estimation of impact of AMR on health and costs

Version 01 4

